|
| Perspective From Industry Leaders |
|
|
| Hudson Holds Reins As Sanofi Makes Strides To Become R&D Powerhouse | Obesity Drugs Will Get Broad Commercial Coverage In 2025 Despite Cost Concerns, Survey Says |
|
For 20 or 30 years, we were not seen as a scientific leader,” the French major’s CEO tells Scrip. Now, things have started... |
The Business Group on Health survey also highlights employers’ complicated attitudes on prescription drug... |
| Licensing & Collaboration Agreements |
|
|
| Xbrane Reveals Urgency To Find A Partner For One Of Two Biosimilars By October | Deal Watch: Lilly Turns To Oblique For Antibody Discovery |
|
Cash is king for fledgling biosimilar companies. Xbrane Biopharma has revealed just how close it is to the edge... |
Plus deals involving Lilly/Oblique, Rafael Holdings/Cyclo, ADCendo/Multitude, Ocuvex/Visiox and more... |
| Next Gen R&D |
|
|
| Biopharma’s Fastest Growing Technology Groups | BridgeBio Bows Out With CAH Gene Therapy Despite Trial Success |
|
The next six years will see rapid growth in several newer pharmaceutical technology groups. In this article... |
The company said the results did not meet the threshold for continued capital investment, giving a boost to... |
| Clinical Trials |
|
|
| Co-Founder Of ‘Anti-CRO’ Talks Building Better Clinical Trials | Ireland Steps Up Efforts To Boost Clinical Trial Performance By Standardizing CTAs |
|
Medtech Insight interviewed Meri Beckwith, co-founder of “anti-CRO” clinical research organization Lindus... |
Standard templates for clinical trial agreements are expected to help do away with the costs and delays arising... |
|
|
|
Citeline Contact Poornachandra Tejasvi .K, 
|
IPA Contact Name: Hari Pranav K |